查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2105029

經導管三尖瓣修復市場規模、佔有率和趨勢分析：按產品類型、適應症、最終用戶和地區分類 - 全球機會分析和行業預測（2026-2036 年）

Transcatheter Tricuspid Valve Repair Market Size, Share & Trends Analysis by Product Type (Coaptation Enhancement Devices, Annuloplasty Systems), Indication, End User, and Geography - Global Opportunity Analysis and Industry Forecast (2026-2036)
出版日期: | 出版商: Meticulous Research | 英文 265 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

全球經導管三尖瓣修復市場預計在2026年達到8.2億美元，並預計2036年將達到16.5億美元。預計在預測期內，該市場將以7.35%的CAGR成長。本報告全面評估了快速發展的結構性心臟疾病（特別是三尖瓣逆流）的現狀，並檢驗了整個價值鏈的市場趨勢、技術進步、競爭格局和未來成長機會。

經導管三尖瓣修復術革新三尖瓣逆流的治療方式，為不適合傳統開胸手術的患者提供了微創替代方案。由於外科手術風險高，三尖瓣逆流的治療歷來不足，但經導管技術已成為恢復瓣膜功能、改善症狀、提高生活品質和改善心臟衰竭預後的重要過程。隨著臨床證據的不斷積累，這些治療方法正被世界各地的醫院和心臟導管室廣泛採用。

本報告提供詳盡的市場評估，分析影響產業成長的技術創新、臨床試驗進展、監管考量和競爭趨勢。報告評估了經導管修復技術如何應對三尖瓣複雜的解剖結構，從邊緣對邊緣修復裝置到環狀軟骨成形術系統，甚至包括針對不適合其他修復方法的解剖結構進行的腔靜脈瓣膜移植。此外，本研究還提供策略性市場預測、細分市場洞察和區域分析，以支持明智的商業和投資決策。

市場動態

大量症狀性三尖瓣逆流（TRICUG）患者有顯著且未滿足的臨床需求，仍是推動市場發展的主要因素。重度TRICUG若不治療，死亡風險極高，但目前僅有少數合格手術條件的患者接受手術治療，導致治療缺口巨大。經導管針灸是彌合這一缺口的有效選擇。領先的臨床試驗評估了經導管緣對緣修復術的積極結果，顯著增強了醫生的信心和患者轉診量，促進了該療法的應用。專用修復系統和術中影像技術（包括3D經食道和心內超音波心動圖）的不斷進步，進一步提高了手術成功率和病人安全性。

儘管發展動力良好，但仍有許多挑戰阻礙其普及。經導管修復器材的高成本，以及手術所需的專業混合手術室設施和多學科心臟團隊的專業知識，可能會限制其在小規模的醫療機構和對成本較為敏感的醫療系統中的應用。三尖瓣的技術複雜性 - 其薄瓣葉、高度可變的瓣環以及與心臟傳導系統的接近性 - 對操作者的技術水準提出了很高的要求。此外，與外科手術修復相比，缺乏關於長期耐久性的全面資料仍然是該領域的重要考慮因素。

儘管如此，該市場仍蘊藏著巨大的長期機會。新興市場不斷完善結構性心臟疾病治療基礎設施，新一代系統在提高耐用性和易植入性方面不斷進步，以應對更嚴重的瓣膜逆流，以及將三尖瓣修復與其他結構性心臟疾病治療方法相結合，為多瓣膜心臟病患者帶來更多可能性，這些都將為未來的成長創造有利條件。此外，心臟節律監測裝置植入數量的不斷增加，也為目的是解決裝置導線引起的逆流的修復技術創造了機會。

細分市場分析

本報告依產品類型、適應症、最終用戶和地區提供詳細的市場分析，幫助相關人員識別高成長業務機會和不斷變化的客戶需求。

依產品類型分類，連接處增強裝置佔據最大的市場佔有率，這得益於其早期獲得的監管批准以及大量臨床資料，這些資料證明了其安全性和有效性，能夠減輕反流的嚴重程度。環狀軟骨成形術系統預計將實現最快的成長，這主要源自於人們日益認知到，與單純的連接處增強相比，環狀軟骨成形術能夠更直接地解決功能性三尖瓣逆流的根本病理問題。

從適應症角度來看，功能性三尖瓣逆流佔比最大，因為其在老年心臟衰竭患者中發生率較高。然而，隨著心臟節律管理裝置植入數量的增加和導線保留修復手術的普及，心律調節器誘發的三尖瓣逆流預計將成長最快。從最終用戶來看，擁有結構性心臟疾病專科計畫的醫院需求量最大，因為它們具備開展此類手術所需的多學科專業知識。

區域分析

本報告對北美、歐洲、亞太、拉丁美洲以及中東和非洲市場進行了全面分析。區域評估考慮了影響市場成長的因素，包括結構性心臟疾病計畫的成熟度、法律規範、償付政策和治療量趨勢。

北美目前佔據全球市場最大佔有率，這得益於其早期採用創新結構性心臟疾病療法、擁有完善的結構性心臟疾病專科醫院體系，以及獲批經導管已通過核准器械的優惠償付政策。歐洲市場也持續穩定成長，這主要得益於其成熟的結構性心臟疾病計畫以及在關鍵市場不斷累積的臨床經驗。

預計亞太地區將在預測期內保持最快成長，這主要得益於醫療基礎設施的快速擴張、心臟衰竭盛行率的上升、經導管治療臨床技術的不斷提高，以及中國和日本等國本土醫療設備製造商的存在。隨著結構性心臟疾病計畫和心臟醫療基礎設施的持續發展，拉丁美洲、中東和非洲地區也將迎來新的機會。

競爭格局

本報告透過檢驗主要市場參與企業的策略定位、設備組合、臨床試驗管線、合作關係、收購、區域擴張努力和近期發展，對競爭格局進行了全面評估。

競爭性基準分析使相關人員能夠根據醫療設備的安全性、易用性以及對各種三尖瓣解剖形態的適應能力來評估公司。本研究還分析了市場參與企業如何透過策略收購擁有新型瓣瓣環成形術和縫合技術的公司來增強自身競爭力，以及他們如何持續投資於目的是獲得監管部門批准和建立醫生信心的大規模關鍵臨床試驗。

本報告涵蓋的主要公司概況包括：Abbott Laboratories、Edwards Lifesciences Corporation、Medtronic plc、Boston Scientific Corporation、MicroPort Scientific Corporation、Venus Medtech (Hangzhou) Inc.、Lepu Medical Technology (Beijing) Co., Ltd.。

如何使用此報告

提供經導管三尖瓣修復市場的準確市場規模估算和長期預測。

本研究評估了臨床試驗證據對經導管修復手術的採用以及醫生對其信心的影響。

依產品類型、適應症、最終用戶和地區來確定高成長機會。

分析新的技術趨勢、臨床開發和創新管線。

根據主要參與者的設備組合、策略措施和競爭優勢進行基準測試。

為產品開發、投資規劃、合作夥伴評估、市場進入和業務擴大策略提供支援。

為醫療設備製造商、醫院、結構性心臟疾病計畫、投資者和顧問提供可操作的市場情報。

主要問題的答案

目前全球經導管三尖瓣修復市場的規模有多大？預計到2036年將如何成長？

哪些臨床、技術和人口因素推動市場成長？

影響該產業發展的主要促進因素、阻礙因素、機會和挑戰是什麼？

預計哪種產品類型、適應症、最終用戶或區域細分市場成長最強勁？

哪個區域市場蘊藏著最具吸引力的商業機會？

在這個市場中營運的主要公司有哪些？它們採用了哪些競爭策略？

在近期臨床試驗結果、合作關係、收購和技術創新中，哪些因素塑造競爭格局？

相關人員如何利用本報告中獲得的市場資訊來支援投資決策、產品開發、競爭基準分析和長期業務策略？

目錄

第1章 市場定義和範圍

第2章 調查方法

第3章 執行摘要

  • 基於細分市場的分析
    • 市場分析：依產品類型
    • 市場分析：依適應症分類
    • 市場分析：依最終用戶分類
    • 市場分析：依地區分類
  • 競爭分析

第4章 市場洞察

  • 影響市場成長的因素
    • 促進因素
      • 未接受治療的TR患者存在大量未被滿足的需求（統計：美國有160萬名患者）
      • 專業經導管修復系統和診斷影像技術的進步
      • 正向的臨床資料（TRILUMINATE試驗成功：減少87%）
    • 抑制因子
      • 高成本和專門的基礎設施要求
      • 技術複雜性和傳導系統干擾的風險
    • 機會
      • 進入新興市場，並建立結構性心臟疾病專科治療中心
      • 開發用於治療心律調節器誘發性三酸甘油酯（TRs）的導線保留修復技術
    • 課題
      • 與手術標準相比，缺乏關於長期耐用性的全面資料。
      • 高成本醫療技術保險償付的障礙
    • 趨勢
      • 過渡到早期療育和新的「暴雨型 TR」分類。
      • 將3D經食道心臟超音波（3D TEE）和經食道心臟超音波（ICE）整合到手術指導中
  • 波特五力分析
  • 監理情勢
  • 價值鏈分析

第5章 全球經導管三尖瓣修復市場：依產品類型分類

  • TEER 夾子
  • 瓣環成形術系統
    • 直接瓣環成形術
    • 間接環瓣環成形術
  • 縫合系統
  • CAVI

第6章 全球經導管三尖瓣修復市場：依適應症分類

  • 功能性三尖瓣逆流（FTR）
  • 退化性三尖瓣逆流
  • 心律調節器誘發的三尖瓣逆流

第7章 全球經導管三尖瓣修復市場：依最終用戶分類

  • 醫院/心臟中心
  • 專科診所
  • 學術研究機構

第8章 全球經導管三尖瓣修復市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 其他亞太國家
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家
  • 中東和非洲

第9章 競爭情勢

  • 關鍵成長策略
  • 競爭儀錶板
  • 供應商市場定位
  • 2025年市場佔有率分析

第10章 公司簡介

  • Abbott Laboratories
  • Edwards Lifesciences Corporation
  • Medtronic plc
  • Boston Scientific Corporation
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Venus Medtech（Hangzhou）Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • 4C Medical Technologies, Inc.
  • Peijia Medical Limited
  • HLT, Inc.（Bracco Group）
  • Structural Heart, Inc.
  • Cardiac Success Ltd.
  • Valcare Medical
  • Mitralix Ltd.
  • CoreMedic GmbH
  • MVRx, Inc.
  • BioVentrix, Inc.
  • Ancora Heart, Inc.

第11章 附錄

簡介目錄
Product Code: MRHC - 1042020

The global Transcatheter Tricuspid Valve Repair market is estimated to be valued at USD 0.82 billion in 2026 and is projected to reach USD 1.65 billion by 2036, expanding at a CAGR of 7.35% during the forecast period. The report provides a comprehensive evaluation of the rapidly evolving structural heart disease landscape addressing tricuspid regurgitation, examining market trends, technological advancements, competitive developments, and future growth opportunities across the value chain.

Transcatheter tricuspid valve repair is transforming the management of tricuspid regurgitation by offering a minimally invasive alternative for patients who are poor candidates for conventional open-heart surgery. As tricuspid regurgitation has historically been undertreated due to the elevated procedural risk associated with surgical repair, transcatheter technologies have become an essential option for restoring valve function and improving symptoms, quality of life, and heart failure outcomes. Hospitals and cardiac catheterization laboratories across the globe are increasingly adopting these therapies as clinical evidence continues to build in their favor.

This report delivers an in-depth assessment of the market by analyzing technological innovations, clinical trial developments, regulatory considerations, and competitive developments influencing industry growth. It evaluates how transcatheter repair technologies are addressing the anatomical complexity of the tricuspid valve, from edge-to-edge coaptation devices to annuloplasty systems and caval valve implantation for anatomies unsuitable for other repair approaches. The study also provides strategic market forecasts, segment-level insights, and regional analysis to support informed business and investment decisions.

Market Dynamics

The substantial unmet clinical need among the large population of patients with symptomatic tricuspid regurgitation remains the primary driver of the market. Severe tricuspid regurgitation carries a high mortality risk if left untreated, yet only a small fraction of eligible patients currently receive surgical treatment, leaving a wide treatment gap that transcatheter options are well positioned to address. Positive results from pivotal clinical trials evaluating transcatheter edge-to-edge repair have significantly boosted physician confidence and patient referrals, reinforcing adoption. Continued advancement in dedicated repair systems and intraprocedural imaging technologies, including three-dimensional transesophageal and intracardiac echocardiography, is further improving procedural success rates and patient safety.

Despite this momentum, several challenges continue to influence adoption. The high cost of transcatheter repair devices and the specialized hybrid operating room infrastructure and multidisciplinary heart team expertise required for these procedures can limit adoption in smaller or cost-sensitive healthcare systems. The technical complexity of the tricuspid valve's thin leaflets, large variable annulus, and proximity to the cardiac conduction system demands a high level of operator skill, and the current lack of extensive long-term durability data relative to surgical repair remains an important consideration for the field.

The market nevertheless presents significant long-term opportunities. Expansion into emerging markets with improving structural heart infrastructure, the development of next-generation systems offering improved durability and easier delivery for more severe regurgitation classifications, and the potential to combine tricuspid repair with other structural heart interventions for patients with multi-valvular disease are expected to create favorable conditions for future growth. The rising volume of cardiac rhythm device implantations is also creating opportunities for repair techniques designed to address device lead-related regurgitation.

Segment Analysis

The report provides detailed market analysis across product type, indication, end user, and geography, enabling stakeholders to identify high-growth business opportunities and evolving customer requirements.

Based on product type, coaptation enhancement devices hold the largest share of the market, supported by early regulatory approvals and the substantial clinical data supporting their safety and efficacy in reducing regurgitation severity. Annuloplasty systems are expected to register the fastest growth, driven by increasing recognition that annular resizing addresses the underlying pathology of functional tricuspid regurgitation more directly than coaptation enhancement alone.

From an indication perspective, functional tricuspid regurgitation accounts for the largest share given its high prevalence among the aging heart failure population, while pacemaker-induced tricuspid regurgitation is expected to grow fastest as cardiac rhythm device implant volumes rise and lead-sparing repair techniques gain adoption. By end user, hospitals with dedicated structural heart programs represent the largest share of demand, supported by the multidisciplinary expertise required for these procedures.

Regional Analysis

The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional evaluations consider structural heart program maturity, regulatory frameworks, reimbursement policies, and procedural volume trends influencing market growth.

North America currently accounts for the largest share of the global market, supported by early adoption of innovative structural heart therapies, a well-established base of hospitals with dedicated structural heart programs, and favorable reimbursement policies for approved transcatheter devices. Europe continues to demonstrate steady growth, underpinned by established structural heart programs and expanding clinical experience across major markets.

Asia-Pacific is expected to register the fastest growth throughout the forecast period, supported by rapid expansion of healthcare infrastructure, rising prevalence of heart failure, and growing clinical expertise in transcatheter interventions, along with the presence of domestic device manufacturers in countries such as China and Japan. Latin America and the Middle East & Africa are also expected to offer emerging opportunities as structural heart programs and cardiac care infrastructure continue to develop.

Competitive Landscape

The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of key market participants, their device portfolios, clinical trial pipelines, partnerships, acquisitions, geographic expansion initiatives, and recent business developments.

Competitive benchmarking enables stakeholders to evaluate companies based on device safety, ease of use, and the ability to treat a broad range of tricuspid anatomies. The study also analyzes how market participants are strengthening their competitive position through strategic acquisitions of companies with novel annuloplasty or suture-based technologies, alongside continued investment in large-scale pivotal clinical trials to secure regulatory approvals and build physician trust.

Key companies profiled in the report include Abbott Laboratories, Edwards Lifesciences Corporation, Medtronic plc, Boston Scientific Corporation, MicroPort Scientific Corporation, Venus Medtech (Hangzhou) Inc., and Lepu Medical Technology (Beijing) Co., Ltd., among others.

How This Report Helps

Provides accurate market size estimates and long-term forecasts for the transcatheter tricuspid valve repair market.

Evaluates the impact of clinical trial evidence on transcatheter repair adoption and physician confidence.

Identifies high-growth opportunities across product types, indications, end users, and geographic regions.

Analyzes emerging technology trends, clinical developments, and innovation pipelines.

Benchmarks leading companies based on device portfolios, strategic initiatives, and competitive positioning.

Supports product development, investment planning, partnership evaluation, market entry, and business expansion strategies.

Delivers actionable market intelligence for medical device manufacturers, hospitals, structural heart programs, investors, and consultants.

Key Questions Answered

What is the current size of the global transcatheter tricuspid valve repair market, and how is it expected to evolve through 2036?

Which clinical, technological, and demographic factors are driving market growth?

What are the major drivers, restraints, opportunities, and challenges influencing industry development?

Which product type, indication, end-user, and regional segments are expected to experience the strongest growth?

Which geographic markets present the most attractive business opportunities?

Who are the leading companies operating in the market, and what competitive strategies are they adopting?

What recent clinical trial results, partnerships, acquisitions, and technological innovations are shaping the competitive landscape?

How can stakeholders leverage market intelligence from this report to support investment decisions, product development, competitive benchmarking, and long-term business strategy?

TABLE OF CONTENTS

1. Market Definition & Scope

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency Considered
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders
  • 2.3. Market Sizing and Forecast
    • 2.3.1. Market Size Estimation Approach
      • 2.3.1.1. Bottom-Up Approach
      • 2.3.1.2. Top-Down Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Assumptions for the Study

3. Executive Summary

  • 3.1. Overview
  • 3.2. Segmental Analysis
    • 3.2.1. Market Analysis, by Product Type
    • 3.2.2. Market Analysis, by Indication
    • 3.2.3. Market Analysis, by End User
    • 3.2.4. Market Analysis, by Geography
  • 3.3. Competitive Analysis

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Drivers
      • 4.2.1.1. High Unmet Need in Untreated TR Population (Stats: 1.6M patients in U.S.)
      • 4.2.1.2. Advancements in Dedicated Transcatheter Repair Systems and Imaging
      • 4.2.1.3. Favorable Clinical Data (TRILUMINATE Trial Success: 87% reduction)
    • 4.2.2. Restraints
      • 4.2.2.1. High Device Costs and Specialized Infrastructure Requirements
      • 4.2.2.2. Technical Complexity and Risk of Conduction System Interference
    • 4.2.3. Opportunities
      • 4.2.3.1. Expansion into Emerging Markets and Specialized Structural Heart Centers
      • 4.2.3.2. Development of Lead-Sparing Repair Techniques for Pacemaker-Induced TR
    • 4.2.4. Challenges
      • 4.2.4.1. Lack of Extensive Long-term Durability Data vs. Surgical Standards
      • 4.2.4.2. Reimbursement Hurdles for High-Cost Medical Technologies
    • 4.2.5. Trends
      • 4.2.5.1. Shift Toward Early Intervention and the New Torrential TR Classification
      • 4.2.5.2. Integration of 3D TEE and ICE in Procedural Guidance
  • 4.3. Porter's Five Forces Analysis
  • 4.4. Regulatory Landscape
  • 4.5. Value Chain Analysis

5. Global Transcatheter Tricuspid Valve Repair Market, by Product Type

  • 5.1. Overview
  • 5.2. Coaptation Enhancement Devices (TEER Clips)
  • 5.3. Annuloplasty Systems
    • 5.3.1. Direct Annuloplasty
    • 5.3.2. Indirect Annuloplasty
  • 5.4. Suture-Based Systems
  • 5.5. Caval Valve Implantation (CAVI)

6. Global Transcatheter Tricuspid Valve Repair Market, by Indication

  • 6.1. Overview
  • 6.2. Functional Tricuspid Regurgitation (FTR)
  • 6.3. Degenerative Tricuspid Regurgitation
  • 6.4. Pacemaker-Induced Tricuspid Regurgitation

7. Global Transcatheter Tricuspid Valve Repair Market, by End User

  • 7.1. Overview
  • 7.2. Hospitals & Cardiac Centers
  • 7.3. Specialty Clinics
  • 7.4. Academic & Research Institutes

8. Global Transcatheter Tricuspid Valve Repair Market, by Geography

  • 8.1. Overview
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. France
    • 8.3.3. U.K.
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Rest of Asia-Pacific
  • 8.5. Latin America
    • 8.5.1. Brazil
    • 8.5.2. Mexico
    • 8.5.3. Rest of Latin America
  • 8.6. Middle East & Africa

9. Competitive Landscape

  • 9.1. Overview
  • 9.2. Key Growth Strategies
  • 9.3. Competitive Dashboard
  • 9.4. Vendor Market Positioning
  • 9.5. Market Share Analysis, 2025

10. Company Profiles

  • 10.1. Abbott Laboratories
  • 10.2. Edwards Lifesciences Corporation
  • 10.3. Medtronic plc
  • 10.4. Boston Scientific Corporation
  • 10.5. Terumo Corporation
  • 10.6. MicroPort Scientific Corporation
  • 10.7. Venus Medtech (Hangzhou) Inc.
  • 10.8. Lepu Medical Technology (Beijing) Co., Ltd.
  • 10.9. 4C Medical Technologies, Inc.
  • 10.10. Peijia Medical Limited
  • 10.11. HLT, Inc. (Bracco Group)
  • 10.12. Structural Heart, Inc.
  • 10.13. Cardiac Success Ltd.
  • 10.14. Valcare Medical
  • 10.15. Mitralix Ltd.
  • 10.16. CoreMedic GmbH
  • 10.17. MVRx, Inc.
  • 10.18. BioVentrix, Inc.
  • 10.19. Ancora Heart, Inc.

11. Appendix